KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 76 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,270,103 | +23.4% | 130,691 | 0.0% | 1.01% | +21.6% |
| Q2 2023 | $1,840,129 | +50.6% | 130,691 | +15.1% | 0.83% | +65.4% |
| Q1 2023 | $1,221,690 | -66.9% | 113,540 | -67.2% | 0.50% | -4.2% |
| Q4 2022 | $3,689,000 | -28.2% | 346,500 | -27.8% | 0.52% | -53.7% |
| Q3 2022 | $5,140,000 | 0.0% | 480,000 | 0.0% | 1.13% | +93.7% |
| Q2 2022 | $5,140,000 | +7.7% | 480,000 | 0.0% | 0.58% | -47.2% |
| Q1 2022 | $4,771,000 | +637.4% | 480,000 | +772.7% | 1.11% | +539.9% |
| Q4 2021 | $647,000 | -88.5% | 55,000 | -88.9% | 0.17% | -83.6% |
| Q3 2021 | $5,646,000 | -18.2% | 495,748 | 0.0% | 1.06% | -11.3% |
| Q2 2021 | $6,905,000 | -24.7% | 495,748 | 0.0% | 1.19% | -28.5% |
| Q1 2021 | $9,176,000 | +4.8% | 495,748 | 0.0% | 1.67% | -1.1% |
| Q4 2020 | $8,759,000 | +15.3% | 495,748 | 0.0% | 1.69% | +1.3% |
| Q3 2020 | $7,594,000 | -39.9% | 495,748 | 0.0% | 1.67% | -45.6% |
| Q2 2020 | $12,631,000 | +64.6% | 495,748 | 0.0% | 3.06% | +51.3% |
| Q1 2020 | $7,674,000 | – | 495,748 | – | 2.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |